Neeraj Agarwal, MD, discusses the safety profile of the combination of enzalutamide and talazoparib in patients with metastatic castration-resistant prostate cancer.
Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, discusses the safety profile of the combination of enzalutamide (Xtandi) and talazoparib (Talzenna) in patients with metastatic castration-resistant prostate cancer (mCRPC).
In part 1 of the phase III TALAPRO-2 study, investigators found that the combination of enzalutamide and talazoparib was generally well tolerated. The fatigue that was reported could be attributed to prior exposure to testosterone suppression, explains Agarwal.
The addition of talazoparib did not increase toxicity, reports Agarwal. Typically, PARP inhibitors account for a unique set of adverse events (AEs) including low white count, anemia, and low platelets; however, these AEs were not compounded by the combination in this safety analysis.